This website uses cookies to enhance the user experience.
P

PALLA PHARMA NORWAY AS918 275 452

Process industry
Limited company
Gruveveien 1 3770 KRAGERØ, Norge

PALLA PHARMA NORWAY AS

Keywords

productionpharmaceuticalsantiserablood fractionsvaccineshomeopathic preparationscontraceptive productsbone buildingdiagnostic preparationspregnancy testsbiotechnological medicinescotton woolgasbandagesdressings

Organization

Chairman of the board
Years since formation
9 years
since Dec 20, 2016
Type
Limited company
VAT registered
Yes
Number of employees
72

Ownership

Number of shares and share classes
30,000
1 share class
Total number of shareholders
1
company
Belongs to group of

Financials

Total operating income 2024
213,177,159
NOK
Annual total result 2024
13,369,064
NOK
Total equity 2024
52,608,967
NOK
Last update: Jul 12, 2025

Management

Management / administration

NameRoleShares
Managing Director/CEO-

Board

NameRoleShares
Chairman-
Board Member-
Board Member-
Board Member-
Alternate Member-
Alternate Member-

Others

NameRoleShares
K
KPMG AS
Auditor-
V
VALUE GROUP AS
Accountant-

Top 10 individual shareholders

NameRoleShares
-
25.58 %
indirectly
-
17.18 %
indirectly
-
10.91 %
indirectly
-
7.56 %
indirectly
-
5.61 %
indirectly
-
5.41 %
indirectly
-
1.39 %
indirectly
-
1.22 %
indirectly
-
1.22 %
indirectly
Last update: Apr 26, 2025

Ownership

Company shareholders

NameShare classTotal number of sharesShare
Ordinary shares
30,000
100 %
Last update: Jun 2, 2025

Group structure

Financials

in NOK

Summary

Year2024202320222021
Total operating income
213,177,159
166,538,915
83,926,355
97,210,828
Annual Total Result
13,369,064
4,542,307
-74,760,802
-106,989,405
Total assets
168,106,466
121,582,436
88,038,052
98,664,588
Total liabilities
115,497,498
82,342,533
89,940,456
286,050,507
Total equity
52,608,967
39,239,903
-1,902,403
-187,385,918

P&L

Year2024202320222021
Total operating income
213,177,159
166,538,915
83,926,355
97,210,828
Total operating costs
193,500,456
159,555,336
158,244,561
201,173,181
Operating result
19,676,703
6,983,580
-74,318,206
-103,962,353
Financial income/costs
-6,307,639
-2,441,273
-442,595
-3,027,052
Profit before tax
13,369,064
4,542,307
-74,760,802
-106,989,405
Total tax & extraordinary income/cost
0
0
0
0
Annual Total Result
13,369,064
4,542,307
-74,760,802
-106,989,405

Balance overview

Year2024202320222021
Total fixed assets
71,771,503
33,811,365
20,223,950
21,822,728
Total current assets
96,334,962
87,771,071
67,814,102
76,841,860
Total assets
168,106,466
121,582,436
88,038,052
98,664,588
Short term debt
88,897,498
55,602,533
34,940,456
240,610,881
Long term debt
26,600,000
26,740,000
55,000,000
45,439,626
Total liabilities
115,497,498
82,342,533
89,940,456
286,050,507
Contributed capital
39,239,903
39,239,903
3,000,000
19,894,234
Retained earnings
13,369,064
0
-4,902,403
-207,280,152
Total equity
52,608,967
39,239,903
-1,902,403
-187,385,918
Total equity and liabilities
168,106,466
121,582,436
88,038,052
98,664,588

Classification

Type of organization
Limited company
Classification of institutional sector
INNL
Domestic sectors
A_IKKE-FIN
Non-financial corporations
2100
Private non-financial incorporated enterprises
Standard industrial classification
C
Main industrial area
Manufacturing
21
Activity
Manufacture of basic pharmaceutical products and pharmaceutical preparations
21.2
Main industrial group
Manufacture of pharmaceutical preparations
21.20
Industrial group
Manufacture of pharmaceutical preparations
21.200
Industrial group
Manufacture of pharmaceutical preparations